Drug Type Single-chain FV antibody fragment |
Synonyms DNX-514 |
Target |
Action inhibitors |
Mechanism TNF inhibitors(Tumor necrosis factor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ankylosing Spondylitis | Preclinical | United States | 31 Aug 2022 | |
| Arthritis, Psoriatic | Preclinical | United States | 31 Aug 2022 | |
| Colitis, Ulcerative | Preclinical | United States | 31 Aug 2022 | |
| Crohn Disease | Preclinical | United States | 31 Aug 2022 | |
| Juvenile Idiopathic Arthritis | Preclinical | United States | 31 Aug 2022 | |
| Plaque psoriasis | Preclinical | United States | 31 Aug 2022 | |
| Rheumatoid Arthritis | Preclinical | United States | 31 Aug 2022 |






